Skip to main content
Top
Published in: Rheumatology International 8/2011

01-08-2011 | Original Article

Screening and evaluating the mimic peptides as a useful serum biomarker of ankylosing spondylitis using a phage display technique

Authors: Min Wang, Xianping Li, Jingwei Chen, Yong Zhou, Hong Cao, Xiang Wu, Hongmin Jiang

Published in: Rheumatology International | Issue 8/2011

Login to get access

Abstract

To screen specific serum biomarker for ankylosing spondylitis (AS) using a phage random peptide library. A phage random peptide library of random peptide 12-mers was immunoscreened with purified immunoglobulin (Ig) G from sera of AS patients. Positive clones obtained after three rounds of biopanning were detected with ELISA and sequenced. Reaction of the screened positive clones with sera from AS patients, systemic lupus erythematosus (SLE) patients, rheumatoid arthritis (RA) patients, osteoarthritis (OA) patients and healthy controls was detected using phage ELISA. Correlation among erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and the absorbance value of the positive clone in phage ELISA was examined in AS patients. Seventeen out of twenty randomly selected phage clones exhibited specific reaction with purified sera IgG from AS patients, among them seven coming from the same clone whose inserted peptide sequence was LALPPLAPNHHH (named “AS1”). Phage ELISA results showed that the positive reaction rate of the AS1 clone was 92.0% with AS patients, significantly different (P < 0.01) from those with SLE patients (56.7%), RA patients (50.0%), OA patients (13.3%), and healthy controls (14.0%). Absorbance value of the AS1 clone in phage ELISA was significantly higher than those in the other groups (P < 0.05). In addition, the absorbance value of the AS1 clone showed no statistically significant correlation with ESR and CRP in AS patients, suggesting that AS1 detects AS patients through a unique mechanism other than inflammation. The short peptide AS1 obtained through screening of a phage random peptide library with purified serum IgG from AS patients can specifically react with the sera of AS patients, and thereby may be a candidate of AS-specific serum biomarkers.
Literature
1.
go back to reference Elyan M, Khan MA (2006) Diagnosing ankylosing spondylitis. J Rheumatol 33(Suppl 78):12–23 Elyan M, Khan MA (2006) Diagnosing ankylosing spondylitis. J Rheumatol 33(Suppl 78):12–23
2.
go back to reference Rudwaleit M, Khan MA, Sieper J (2005) The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 52:1000–1008PubMedCrossRef Rudwaleit M, Khan MA, Sieper J (2005) The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 52:1000–1008PubMedCrossRef
3.
go back to reference Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23:61–66PubMed Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23:61–66PubMed
4.
go back to reference Salvarani C, Fries W (2009) Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 15:2449–2455PubMedCrossRef Salvarani C, Fries W (2009) Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 15:2449–2455PubMedCrossRef
6.
go back to reference Zeng QY, Chen R, Darmawan J, Xiao ZY, Chen SB, Wigley R, Le Chen S, Zhang NZ (2008) Rheumatic diseases in China. Arthritis Res Ther 10:R17PubMedCrossRef Zeng QY, Chen R, Darmawan J, Xiao ZY, Chen SB, Wigley R, Le Chen S, Zhang NZ (2008) Rheumatic diseases in China. Arthritis Res Ther 10:R17PubMedCrossRef
7.
go back to reference López de Castro JA (2007) HLA-B27 and the pathogenesis of spondyloarthropathies. Immunol Lett 108:27–33PubMedCrossRef López de Castro JA (2007) HLA-B27 and the pathogenesis of spondyloarthropathies. Immunol Lett 108:27–33PubMedCrossRef
8.
go back to reference Sonkar GK, Usha SS, Singh S (2008) Is HLA-B27 a useful test in the diagnosis of juvenile spondyloarthropathies? Singapore Med J 49:795–799PubMed Sonkar GK, Usha SS, Singh S (2008) Is HLA-B27 a useful test in the diagnosis of juvenile spondyloarthropathies? Singapore Med J 49:795–799PubMed
9.
go back to reference Fussell H, Nesbeth D, Lenart I, Campbell EC, Lynch S, Santos S, Gould K, Powis SJ, Antoniou AN (2008) Novel detection of in vivo HLA-B27 conformations correlates with ankylosing spondylitis association. Arthritis Rheum 58:3419–3424PubMedCrossRef Fussell H, Nesbeth D, Lenart I, Campbell EC, Lynch S, Santos S, Gould K, Powis SJ, Antoniou AN (2008) Novel detection of in vivo HLA-B27 conformations correlates with ankylosing spondylitis association. Arthritis Rheum 58:3419–3424PubMedCrossRef
10.
go back to reference Gran JT, Husby G (2003) Epidemiology of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, 3rd edn. Mosby, London, pp 1153–1159 Gran JT, Husby G (2003) Epidemiology of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, 3rd edn. Mosby, London, pp 1153–1159
11.
go back to reference Wang M, Yi XY, Li XP, Zhou DM, Larry M, Zeng XF (2005) Phage displaying peptides mimic schistosoma antigenic epitopes selected by rat natural antibodies and protective immunity induced by their immunization in mice. World J Gastroenterol 11(19):2960–2966PubMed Wang M, Yi XY, Li XP, Zhou DM, Larry M, Zeng XF (2005) Phage displaying peptides mimic schistosoma antigenic epitopes selected by rat natural antibodies and protective immunity induced by their immunization in mice. World J Gastroenterol 11(19):2960–2966PubMed
12.
go back to reference Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361–369PubMedCrossRef Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361–369PubMedCrossRef
13.
go back to reference Shaikh SA (2007) Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment. J Can Chiropr Assoc 51:249–260PubMed Shaikh SA (2007) Ankylosing spondylitis: recent breakthroughs in diagnosis and treatment. J Can Chiropr Assoc 51:249–260PubMed
14.
15.
go back to reference Uhlar CM, Whitehead AS (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265:501–523PubMedCrossRef Uhlar CM, Whitehead AS (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265:501–523PubMedCrossRef
16.
go back to reference O’Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B (2000) Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res 2:142–144PubMedCrossRef O’Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B (2000) Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res 2:142–144PubMedCrossRef
17.
go back to reference Vallon R, Freuler F, Desta-Tsedu N, Robeva A, Dawson J, Wenner P, Engelhardt P, Boes L, Schnyder J, Tschopp C, Urfer R, Baumann G (2001) Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol 166:2801–2807PubMed Vallon R, Freuler F, Desta-Tsedu N, Robeva A, Dawson J, Wenner P, Engelhardt P, Boes L, Schnyder J, Tschopp C, Urfer R, Baumann G (2001) Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol 166:2801–2807PubMed
18.
go back to reference Shimojima Y, Matsuda M, Gono T, Ishii W, Ikeda S (2005) Serum amyloid A as a potent therapeutic marker in a refractory patient with polymyalgia rheumatica. Intern Med 44:1009–1012PubMedCrossRef Shimojima Y, Matsuda M, Gono T, Ishii W, Ikeda S (2005) Serum amyloid A as a potent therapeutic marker in a refractory patient with polymyalgia rheumatica. Intern Med 44:1009–1012PubMedCrossRef
19.
go back to reference Salazar A, Pintó X, Mañá J (2001) Serum amyloid A and high-density lipoprotein cholesterol: serum markers of inflammation in sarcoidosis and other systemic disorders. Eur J Clin Invest 31:1070–1077PubMedCrossRef Salazar A, Pintó X, Mañá J (2001) Serum amyloid A and high-density lipoprotein cholesterol: serum markers of inflammation in sarcoidosis and other systemic disorders. Eur J Clin Invest 31:1070–1077PubMedCrossRef
20.
go back to reference Jung SY, Park MC, Park YB, Lee SK (2007) Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J 48:218–224PubMedCrossRef Jung SY, Park MC, Park YB, Lee SK (2007) Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J 48:218–224PubMedCrossRef
21.
go back to reference Zeng QY, Chen R, Darmawan J, Xiao ZY, Chen SB, Wigley R, Le Chen S, Zhang NZ (2008) Rheumatic diseases in China. Arthritis Res Ther 10:106–116CrossRef Zeng QY, Chen R, Darmawan J, Xiao ZY, Chen SB, Wigley R, Le Chen S, Zhang NZ (2008) Rheumatic diseases in China. Arthritis Res Ther 10:106–116CrossRef
22.
go back to reference de Lopez Castro JA (2007) HLA-B27 and the pathogenesis of spondyloarthropathies. Immunol Lett 108:27–33CrossRef de Lopez Castro JA (2007) HLA-B27 and the pathogenesis of spondyloarthropathies. Immunol Lett 108:27–33CrossRef
23.
go back to reference Braun J, Sieper J (2006) Early diagnosis of spondyloarthritis. Nat Clin Pract Rheumatol 2(10):536–545PubMedCrossRef Braun J, Sieper J (2006) Early diagnosis of spondyloarthritis. Nat Clin Pract Rheumatol 2(10):536–545PubMedCrossRef
24.
go back to reference Reveille JD (2006) Major histocompatibility genes and ankylosing spondylitis. Best Pract Res Clin Rheumatol 20:601–609PubMedCrossRef Reveille JD (2006) Major histocompatibility genes and ankylosing spondylitis. Best Pract Res Clin Rheumatol 20:601–609PubMedCrossRef
25.
go back to reference Wei JC, Tsai WC, Lin HS, Tsai CY, Chou CT (2004) HLA-B60 and B61 are strongly associated with ankylosing spondylitis in HLA-B27-negative Taiwan Chinese patients. Rheumatology (Oxford) 43:839–842CrossRef Wei JC, Tsai WC, Lin HS, Tsai CY, Chou CT (2004) HLA-B60 and B61 are strongly associated with ankylosing spondylitis in HLA-B27-negative Taiwan Chinese patients. Rheumatology (Oxford) 43:839–842CrossRef
26.
go back to reference Yang C, Gu J, Rihl M, Baeten D, Huang F, Zhao M, Zhang H, Maksymowych WP, De Keyser F, Veys EM, Yu DT (2004) Serum levels of matrix metalloproteinase 3 and macrophage colony stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 51:691–699PubMedCrossRef Yang C, Gu J, Rihl M, Baeten D, Huang F, Zhao M, Zhang H, Maksymowych WP, De Keyser F, Veys EM, Yu DT (2004) Serum levels of matrix metalloproteinase 3 and macrophage colony stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 51:691–699PubMedCrossRef
27.
go back to reference Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, Liang TH, Liao HT, Tsai CY, Wei JC, Chou CT (2006) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 45:414–420CrossRef Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, Liang TH, Liao HT, Tsai CY, Wei JC, Chou CT (2006) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 45:414–420CrossRef
28.
go back to reference Maksymowych WP, Landewé R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, Poole AR, Wang N, van der Heijde D (2007) Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56:1846–1853PubMedCrossRef Maksymowych WP, Landewé R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, Poole AR, Wang N, van der Heijde D (2007) Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56:1846–1853PubMedCrossRef
29.
go back to reference Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166PubMedCrossRef Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166PubMedCrossRef
30.
go back to reference Callen JP (2007) Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg 26:6–14PubMedCrossRef Callen JP (2007) Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg 26:6–14PubMedCrossRef
31.
go back to reference Mansour M, Cheema GS, Naguwa SM, Greenspan A, Borchers AT, Keen CL, Gershwin ME (2007) Ankylosing spondylitis: a contemporary perspective on diagnosis and treatment. Semin Arthritis Rheum 36:210–223PubMedCrossRef Mansour M, Cheema GS, Naguwa SM, Greenspan A, Borchers AT, Keen CL, Gershwin ME (2007) Ankylosing spondylitis: a contemporary perspective on diagnosis and treatment. Semin Arthritis Rheum 36:210–223PubMedCrossRef
32.
go back to reference Goffinet M, Chinestra P, Lajoie-Mazenc I, Medale-Giamarchi C, Favre G, Faye JC (2008) Identification of a GTP-bound Rho specific scFv molecular sensor by phage display selection. BMC Biotechnol 8:34–47PubMedCrossRef Goffinet M, Chinestra P, Lajoie-Mazenc I, Medale-Giamarchi C, Favre G, Faye JC (2008) Identification of a GTP-bound Rho specific scFv molecular sensor by phage display selection. BMC Biotechnol 8:34–47PubMedCrossRef
33.
go back to reference Nizak C, Monier S, del Nery E, Moutel S, Goud B, Perez F (2003) Recombinant antibodies to the small GTPase Rab6 as conformation sensors. Science 300:984–987PubMedCrossRef Nizak C, Monier S, del Nery E, Moutel S, Goud B, Perez F (2003) Recombinant antibodies to the small GTPase Rab6 as conformation sensors. Science 300:984–987PubMedCrossRef
34.
go back to reference Chappel JA, He M, Kang AS (1998) Modulation of antibody display on M13 filamentous phage. J Immunol Methods 221:25–34PubMedCrossRef Chappel JA, He M, Kang AS (1998) Modulation of antibody display on M13 filamentous phage. J Immunol Methods 221:25–34PubMedCrossRef
35.
go back to reference Schooltink H, Rose-John S (2005) Designing cytokine variants by phage-display. Comb Chem High Throughput Screen 8:173–179PubMedCrossRef Schooltink H, Rose-John S (2005) Designing cytokine variants by phage-display. Comb Chem High Throughput Screen 8:173–179PubMedCrossRef
36.
go back to reference Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W (2006) Display technologies: application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev 58:1622–1654PubMedCrossRef Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W (2006) Display technologies: application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev 58:1622–1654PubMedCrossRef
37.
go back to reference Soykut EA, Dudak FC, Boyaci IH (2008) Selection of staphylococcal enterotoxin B (SEB)-binding peptide using phage display technology. Biochem Biophys Res Commun 370:104–108PubMedCrossRef Soykut EA, Dudak FC, Boyaci IH (2008) Selection of staphylococcal enterotoxin B (SEB)-binding peptide using phage display technology. Biochem Biophys Res Commun 370:104–108PubMedCrossRef
Metadata
Title
Screening and evaluating the mimic peptides as a useful serum biomarker of ankylosing spondylitis using a phage display technique
Authors
Min Wang
Xianping Li
Jingwei Chen
Yong Zhou
Hong Cao
Xiang Wu
Hongmin Jiang
Publication date
01-08-2011
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 8/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1403-8

Other articles of this Issue 8/2011

Rheumatology International 8/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.